Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 15 | 2022 | 839 | 3.660 |
Why?
|
| Acute Kidney Injury | 4 | 2023 | 232 | 1.550 |
Why?
|
| Immunosuppressive Agents | 6 | 2021 | 514 | 1.500 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 2 | 2019 | 15 | 1.390 |
Why?
|
| Graft Rejection | 7 | 2021 | 458 | 1.360 |
Why?
|
| Calcineurin Inhibitors | 2 | 2018 | 24 | 1.150 |
Why?
|
| Tissue and Organ Procurement | 2 | 2022 | 164 | 0.900 |
Why?
|
| Graft Survival | 8 | 2021 | 465 | 0.870 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 161 | 0.790 |
Why?
|
| Pharmacology, Clinical | 1 | 2021 | 13 | 0.780 |
Why?
|
| Clinical Medicine | 1 | 2021 | 20 | 0.770 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 143 | 0.770 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 155 | 0.770 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 154 | 0.770 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 121 | 0.750 |
Why?
|
| Tacrolimus | 4 | 2021 | 127 | 0.750 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 693 | 0.740 |
Why?
|
| Donor Selection | 1 | 2020 | 29 | 0.730 |
Why?
|
| Betacoronavirus | 2 | 2020 | 116 | 0.730 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 1 | 2019 | 3 | 0.730 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 232 | 0.720 |
Why?
|
| Arteriovenous Fistula | 1 | 2019 | 25 | 0.710 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2019 | 31 | 0.710 |
Why?
|
| Amyloidosis | 1 | 2019 | 48 | 0.700 |
Why?
|
| Interprofessional Relations | 1 | 2021 | 188 | 0.690 |
Why?
|
| Mycophenolic Acid | 1 | 2018 | 62 | 0.660 |
Why?
|
| Renal Artery Obstruction | 1 | 2018 | 29 | 0.660 |
Why?
|
| Arthroplasty, Replacement | 1 | 2019 | 48 | 0.660 |
Why?
|
| Patient Care Team | 1 | 2021 | 311 | 0.660 |
Why?
|
| Kidney Glomerulus | 1 | 2019 | 155 | 0.650 |
Why?
|
| Kidney Failure, Chronic | 4 | 2023 | 365 | 0.640 |
Why?
|
| Angioplasty, Balloon | 1 | 2018 | 110 | 0.620 |
Why?
|
| Renal Dialysis | 4 | 2021 | 174 | 0.610 |
Why?
|
| Pre-Eclampsia | 1 | 2018 | 202 | 0.580 |
Why?
|
| Hypertension | 3 | 2021 | 1531 | 0.520 |
Why?
|
| Humans | 35 | 2023 | 68525 | 0.520 |
Why?
|
| Drug Substitution | 1 | 2014 | 19 | 0.480 |
Why?
|
| Treatment Outcome | 7 | 2021 | 7028 | 0.460 |
Why?
|
| Sirolimus | 1 | 2014 | 118 | 0.450 |
Why?
|
| Kidney | 6 | 2022 | 945 | 0.380 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 938 | 0.380 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 1241 | 0.380 |
Why?
|
| Antilymphocyte Serum | 2 | 2020 | 52 | 0.370 |
Why?
|
| Retrospective Studies | 9 | 2022 | 7264 | 0.370 |
Why?
|
| Tissue Donors | 2 | 2022 | 195 | 0.360 |
Why?
|
| Adult | 13 | 2022 | 21375 | 0.340 |
Why?
|
| Middle Aged | 12 | 2022 | 21119 | 0.290 |
Why?
|
| Cohort Studies | 3 | 2021 | 2356 | 0.260 |
Why?
|
| Male | 13 | 2022 | 37281 | 0.260 |
Why?
|
| Female | 13 | 2022 | 38015 | 0.260 |
Why?
|
| Survival Rate | 3 | 2021 | 1055 | 0.230 |
Why?
|
| Aged | 9 | 2022 | 14842 | 0.230 |
Why?
|
| Insufflation | 1 | 2022 | 4 | 0.230 |
Why?
|
| Pneumoperitoneum | 1 | 2022 | 7 | 0.230 |
Why?
|
| Hypokalemia | 1 | 2022 | 12 | 0.220 |
Why?
|
| Hyperkalemia | 1 | 2022 | 21 | 0.220 |
Why?
|
| Peritoneal Dialysis | 1 | 2022 | 30 | 0.220 |
Why?
|
| Policy | 1 | 2022 | 58 | 0.220 |
Why?
|
| Diabetic Nephropathies | 1 | 2023 | 161 | 0.210 |
Why?
|
| China | 2 | 2021 | 138 | 0.210 |
Why?
|
| Hematoma, Subdural | 1 | 2021 | 19 | 0.210 |
Why?
|
| Creatinine | 2 | 2020 | 243 | 0.210 |
Why?
|
| Incidence | 3 | 2022 | 1582 | 0.210 |
Why?
|
| Central Venous Catheters | 1 | 2021 | 19 | 0.200 |
Why?
|
| Risk Factors | 6 | 2021 | 5719 | 0.200 |
Why?
|
| No-Show Patients | 1 | 2021 | 9 | 0.200 |
Why?
|
| alpha-Fetoproteins | 1 | 2021 | 22 | 0.200 |
Why?
|
| Catheter-Related Infections | 1 | 2021 | 43 | 0.200 |
Why?
|
| Swine | 1 | 2022 | 672 | 0.190 |
Why?
|
| Biopsy | 2 | 2020 | 539 | 0.190 |
Why?
|
| CD40 Ligand | 1 | 2020 | 14 | 0.190 |
Why?
|
| Thrombophilia | 1 | 2020 | 21 | 0.190 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 201 | 0.190 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2020 | 37 | 0.190 |
Why?
|
| Living Donors | 1 | 2022 | 160 | 0.190 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 40 | 0.190 |
Why?
|
| Urinalysis | 1 | 2020 | 27 | 0.190 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 79 | 0.180 |
Why?
|
| Pandemics | 2 | 2020 | 346 | 0.180 |
Why?
|
| Nephritis, Interstitial | 1 | 2020 | 14 | 0.180 |
Why?
|
| Nephrosis, Lipoid | 1 | 2019 | 9 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 76 | 0.180 |
Why?
|
| Brain Death | 1 | 2020 | 34 | 0.180 |
Why?
|
| Sclerosis | 1 | 2019 | 32 | 0.180 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 39 | 0.180 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 1851 | 0.180 |
Why?
|
| Transplant Recipients | 1 | 2021 | 109 | 0.180 |
Why?
|
| Hypoxia | 1 | 2020 | 169 | 0.180 |
Why?
|
| Eosinophilia | 1 | 2020 | 47 | 0.180 |
Why?
|
| Bacteremia | 1 | 2021 | 155 | 0.180 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 163 | 0.160 |
Why?
|
| Postpartum Period | 1 | 2018 | 67 | 0.160 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 361 | 0.160 |
Why?
|
| Proteinuria | 1 | 2018 | 136 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2018 | 107 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 274 | 0.160 |
Why?
|
| Time Factors | 2 | 2018 | 4655 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2021 | 335 | 0.160 |
Why?
|
| Liver Transplantation | 1 | 2021 | 400 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2021 | 714 | 0.150 |
Why?
|
| Acute Disease | 1 | 2018 | 658 | 0.150 |
Why?
|
| Patient Selection | 1 | 2021 | 592 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 334 | 0.150 |
Why?
|
| Cognition | 1 | 2020 | 512 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1139 | 0.140 |
Why?
|
| Algorithms | 1 | 2021 | 1194 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1054 | 0.130 |
Why?
|
| United States | 2 | 2019 | 7335 | 0.120 |
Why?
|
| Isoantibodies | 1 | 2014 | 35 | 0.120 |
Why?
|
| Telemedicine | 1 | 2021 | 699 | 0.110 |
Why?
|
| Pregnancy | 1 | 2018 | 2331 | 0.110 |
Why?
|
| Young Adult | 2 | 2020 | 5708 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 1085 | 0.100 |
Why?
|
| South Carolina | 1 | 2018 | 2750 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 503 | 0.100 |
Why?
|
| Animals | 3 | 2022 | 20877 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2021 | 356 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2023 | 3702 | 0.060 |
Why?
|
| Allopurinol | 1 | 2023 | 36 | 0.060 |
Why?
|
| Linagliptin | 1 | 2023 | 6 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2021 | 1447 | 0.060 |
Why?
|
| Cysteine | 1 | 2023 | 112 | 0.060 |
Why?
|
| Abdomen | 1 | 2022 | 80 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 168 | 0.050 |
Why?
|
| Egypt | 1 | 2021 | 5 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 4843 | 0.050 |
Why?
|
| Appointments and Schedules | 1 | 2021 | 47 | 0.050 |
Why?
|
| Plasmapheresis | 1 | 2020 | 18 | 0.050 |
Why?
|
| Allografts | 1 | 2020 | 63 | 0.050 |
Why?
|
| Immunologic Memory | 1 | 2020 | 75 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2020 | 82 | 0.050 |
Why?
|
| Maintenance Chemotherapy | 1 | 2020 | 10 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2020 | 42 | 0.050 |
Why?
|
| Rabbits | 1 | 2020 | 509 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2021 | 222 | 0.050 |
Why?
|
| Eosinophils | 1 | 2020 | 60 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2020 | 42 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 266 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 69 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2020 | 272 | 0.040 |
Why?
|
| Critical Illness | 1 | 2020 | 191 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2019 | 134 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 248 | 0.040 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2019 | 50 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 2019 | 136 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 163 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 880 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2021 | 631 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 955 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2020 | 1039 | 0.040 |
Why?
|
| Phenotype | 1 | 2020 | 946 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 497 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2020 | 446 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 1037 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1548 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1593 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 977 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 1026 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2004 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2021 | 1615 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2014 | 82 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2014 | 42 | 0.030 |
Why?
|
| Child | 1 | 2020 | 6400 | 0.020 |
Why?
|